A case of "refractory" lupus erythematosus profundus responsive to rituximab [case report].

Hdl Handle:
http://hdl.handle.net/10147/207523
Title:
A case of "refractory" lupus erythematosus profundus responsive to rituximab [case report].
Authors:
McArdle, Adrian; Baker, Joshua F
Affiliation:
St Vincent's University Hospital, Elm Park, Dublin 4, Ireland.
Citation:
Clin Rheumatol. 2009 Jun;28(6):745-6. Epub 2009 Apr 3.
Journal:
Clinical rheumatology
Issue Date:
1-Feb-2012
URI:
http://hdl.handle.net/10147/207523
DOI:
10.1007/s10067-009-1158-3
PubMed ID:
19343472
Abstract:
Lupus erythematosus profundus is a rare complication of systemic lupus erythematosus characterized by the presence of deep, tender subcutaneous nodules. A 22-year-old African-American female with extensive lupus profundus resistant to conventional therapies was treated with two infusions of the anti-CD20 monoclonal antibody, rituximab, at a dosage of 1,000 mg each. The patient demonstrated a remarkable clinical response as indicated by the disappearance of the nodules. B-cell depletion therapy with rituximab used alone or in combination with other therapies may be a viable option in patients with lupus profundus refractory to current therapies.
Language:
eng
MeSH:
Adult; Antibodies, Monoclonal/*therapeutic use; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents/*therapeutic use; Female; Humans; Panniculitis, Lupus Erythematosus/*drug therapy; Treatment Outcome
ISSN:
1434-9949 (Electronic); 0770-3198 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorMcArdle, Adrianen_GB
dc.contributor.authorBaker, Joshua Fen_GB
dc.date.accessioned2012-02-01T10:30:14Z-
dc.date.available2012-02-01T10:30:14Z-
dc.date.issued2012-02-01T10:30:14Z-
dc.identifier.citationClin Rheumatol. 2009 Jun;28(6):745-6. Epub 2009 Apr 3.en_GB
dc.identifier.issn1434-9949 (Electronic)en_GB
dc.identifier.issn0770-3198 (Linking)en_GB
dc.identifier.pmid19343472en_GB
dc.identifier.doi10.1007/s10067-009-1158-3en_GB
dc.identifier.urihttp://hdl.handle.net/10147/207523-
dc.description.abstractLupus erythematosus profundus is a rare complication of systemic lupus erythematosus characterized by the presence of deep, tender subcutaneous nodules. A 22-year-old African-American female with extensive lupus profundus resistant to conventional therapies was treated with two infusions of the anti-CD20 monoclonal antibody, rituximab, at a dosage of 1,000 mg each. The patient demonstrated a remarkable clinical response as indicated by the disappearance of the nodules. B-cell depletion therapy with rituximab used alone or in combination with other therapies may be a viable option in patients with lupus profundus refractory to current therapies.en_GB
dc.language.isoengen_GB
dc.subject.meshAdulten_GB
dc.subject.meshAntibodies, Monoclonal/*therapeutic useen_GB
dc.subject.meshAntibodies, Monoclonal, Murine-Deriveden_GB
dc.subject.meshAntirheumatic Agents/*therapeutic useen_GB
dc.subject.meshFemaleen_GB
dc.subject.meshHumansen_GB
dc.subject.meshPanniculitis, Lupus Erythematosus/*drug therapyen_GB
dc.subject.meshTreatment Outcomeen_GB
dc.titleA case of "refractory" lupus erythematosus profundus responsive to rituximab [case report].en_GB
dc.contributor.departmentSt Vincent's University Hospital, Elm Park, Dublin 4, Ireland.en_GB
dc.identifier.journalClinical rheumatologyen_GB
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.